Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients

9Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Although numerous cytokines influence proliferation and progression of multiple myeloma (MM), a relevant action in the onset of the disease also seems to be played by the oxidative state. Patients and Methods: In the present study we evaluated the concentrations of interleukin-8 (IL-8) and soluble receptor of advanced glycation end products (sRAGE) in patients with MM, assessing the existing variations with respect to a control group and the possible existence of correlations between these molecules and the biological variables or the presence of a correlation between IL-8 and sRAGE. The study was conducted on 33 patients affected by MM compared to 39 healthy subjects. Results: IL-8 and sRAGE levels were significantly higher in MM patients compared to healthy subjects. sRAGE and IL-8 evidence no significant linear correlation. Furthermore, IL-8 was significantly increased in both sexes, but we found a slight variation for females compared to males. Conclusion: IL-8 could play an important role in the onset of MM and the progression of bone disease, while the increased sRAGE values would seem to have a protective action in MM patients. Further studies on animal models may clarify the real impact of introducing modulation of IL-8 and sRAGE levels.

Cite

CITATION STYLE

APA

Allegra, A., Pace, E., Tartarisco, G., Innao, V., Di Salvo, E., Allegra, A. G., … Gangemi, S. (2020). Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients. Anticancer Research, 40(3), 1443–1449. https://doi.org/10.21873/anticanres.14086

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free